Schedule 13G ownership disclosure
Keros Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 492327101
Event date: 2025-10-15
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLC
Shares: 2,418,984.00 · Class: 7.9%
- KEVIN TANG
Shares: 2,418,984.00 · Class: 7.9%
- TANG CAPITAL PARTNERS, LP
Shares: 1,579,237.00 · Class: 5.2%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 839,747.00 · Class: 2.7%
- TANG CAPITAL PARTNERS III, INC
Shares: 0.00 · Class: 0.0%
- TANG CAPITAL PARTNERS IV, INC
Shares: 0.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-015219
- Form type
- SCHEDULE 13G
- Filer
- Keros Therapeutics, Inc.
- CIK
- CIK 1664710
- Filed
- Oct 22, 2025
- Reporting period
- Oct 15, 2025
- Description
- Schedule 13G beneficial ownership